Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204905 · ClinicalTrials.gov registry record · NA
R5 Integrase Study in HIV-1 Naive Patients
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01204905 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 7 participants.
The verdict
NCT01204905, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients. The study will enroll 7 antiretroviral naïve patients with CD4 counts ≥ 350 and viral loads \> 5,000. The subjects will be followed for 48 weeks. The combination of these two agents has the potential to be a potent regimen with minimal metabolic complications. However, they have not been studied in combination previously. This pilot study proposes to evaluate this combination in antiretroviral naïve patients to document the safety and efficacy of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications.
Interventions
- DRUG Raltegravir and Maraviroc in combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-05-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204905
The ClinicalTrials.gov registry entry for NCT01204905 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir and Maraviroc in combination is the first listed.
NCT01204905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204905 about?
NCT01204905 is a clinical study titled "R5 Integrase Study in HIV-1 Naive Patients". This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients. The study will enroll 7 antiretroviral naïve patients with CD4 counts ≥ 350 and viral loads \> 5,000. The subjects will be followed for 48 weeks. The combination of these...
What is the current status of trial NCT01204905?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2010-09. Estimated completion is 2014-05-16.
What interventions are being tested in trial NCT01204905?
The interventions under investigation include: Raltegravir and Maraviroc in combination (DRUG).
Who is sponsoring clinical trial NCT01204905?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.